• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » FDA device chief under fire: Did Dr. Jeffrey Shuren lie to Congress?

FDA device chief under fire: Did Dr. Jeffrey Shuren lie to Congress?

March 10, 2011 By MassDevice staff

Dr. Jeffrey Shuren of the FDA

Shuren

MASSDEVICE ON CALL: An evident untruth made during questioning by a U.S. House committee is landing Dr. Jeffrey Shuren, head of the FDA’ medical device branch, in hot water with scientists and bloggers.

Testifying before a House Energy & Commerce Committee on direct-to-consumer genetic tests last summer, Shuren told Rep. Henry Waxman (D-Calif.) that companies that make the tests do not conduct their own research.

Read about the FDA’s decision on direct-to-consumer genetic testing

"From the information we know, they’re not adding — they’re not doing their own research on the genetic profiles, but they’re interpreting the studies that have been performed by others," Shuren said during his July 22, 2010 testimony.

But just two days earlier, according to a video posted on FDAblog.org, Shuren attended a presentation by 23andme founder Anne Wojcicki detailing her company’s studies of its database of human genetic information.

It’s an especially sensitive issue given an FDA panel’s vote yesterday to recommend that the federal watchdog agency require a doctor to dispense DTC genetic tests. Genomics researchers and science bloggers hate that idea, arguing that the benefits for patients who delve into their genomes far outweigh any potential risks.

But it’s unclear from the FDAblog.org video, which contains only snippets of Shuren and Wojcicki, whether Shuren is speaking about all companies that offer home genetic tests, or merely some players in that space. Calls and emails to the FDA seeking comment were not immediately returned.

The blogosphere, undeterred, was quick to pounce. "Did the FDA’s Jeffrey Shuren mislead a Congressional hearing?" asked Wired magazine’s Daniel MacArthur.

"If last year’s monkey trial hearings were predicated on testimony that turns out to have been anything less than cricket, then — in my mind, at least — it calls into question whether the self-righteousness of those who were doing the finger-pointing ought to be taken at face value,” added Misha Angrist on his GenomeBoy blog.

"This is a power grab, this is not about safety or ethics," fulminated Razib Khan on his Gene Expression blog at Discover. "Let’s make our voices heard. If they take away our rights because we’re silent, we have only ourselves to blame. If they take aware our rights despite our efforts, we’ll set up the infrastructure for the day when we can take back what is ours" [emphasis his].

Here’s a look at the FDAblog video that kicked up the fuss:

Are you sick of healthcare reform yet?

They sure aren’t in Washington, where Rep. Mike Rogers (R-Mich.) is pushing a measure that would allow all Americans to seeka waiver from the healthcare reform law’s individual mandate and Dept. of Health & Human Services secretary Kathleen Sebelius warned that de-funding the law would cut off Medicare payments for millions of elderly Americans.

Meanwhile, in North Carolina, a GOP bid to exempt Tar Heel State residents from the individual mandate fell by the wayside (paid). Further south in Florida, the scene of a court ruling that the law is unconstitutional, the Office of Insurance Regulation says it will not enforce any of the new rules enshrined in the Patient Protection & Affordable Care Act.

The beat goes on… and on… and on…

Docs look to sidestep insurers

There’s a growing move afoot among medical practices to sidestep health insurers altogether in favor of collecting a monthly "membership fee" from their patients, according to the Washington Post:

"Seattle-based Qliance Medical Management’s three clinics typically charge a patient about $65 a month for unlimited access to the practice’s 12 physicians and nurse practitioners. (Fees vary depending on the level of service and the patient’s age.) Office appointments last up to an hour, and clinics have evening and weekend hours, with e-mail and phone access to clinicians as well. Routine preventive care and many in-office procedures are free; patients pay for lab work and other outside services “at or near” cost, and they get discounts on many medications.

"The average $700 to $800 per patient that Qliance receives annually in membership fees is up to three times more than a doctor in a standard insurance-based practice might make per patient, says Norm Wu, the company’s president and chief executive."

Cancer survivors quadrupled from 1971 to 2007

The number of people who survived cancer over a 36-year span nearly quadrupled, according the Centers for Disease Control.

That’s due to earlier detection, improved diagnostics, more effective treatments, improved follow-up and the graying U.S. population, the Los Angeles Times reports.

JAMA taps new editor

The Journal of the American Medical Assn. named a new editor, Dr. Howard Bauchner of the Boston University School of Medicine, to replace the retiring Dr. Catherine DeAngelis, according to Reuters.

Filed Under: Food & Drug Administration (FDA), News Well

In case you missed it

  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans

RSS From Medical Design & Outsourcing

  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS